2022 SEMI-ANNUAL REPORT

MIDDLEFIELD HEALTHCARE DIVIDEND FUND

(formerly Global Healthcare Dividend Fund)

MMF

MIDDLEFIELD MUTUAL FUNDS

MIDDLEFIELD CORPORATE PROFILE

The Middlefield Group was established in 1979 and is a Specialty Investment Manager which creates investment products designed to balance risk and return to meet the demanding requirements of Financial Advisors and their clients. These financial products include Exchange-Traded Funds, Mutual Funds, Private and Public Resource Funds, Split Share Corporations, Venture Capital Assets, TSX Publicly Traded Funds and Real Estate Investment Funds and Partnerships.

Middlefield's investment team comprises portfolio managers, analysts and traders. While all of our investment products are designed and managed by Middlefield professionals, some involve strategic partnerships with other "best-in-class" firms that bring unique value to our product offerings. In 2014, we entered into an exclusive arrangement with SSR, LLC, based in Stamford, Connecticut. They provide specialized research into sectors of the economy such as Healthcare and Innovation Technology. SSR is an independent investment firm whose analysts have been highly ranked and are recognized as leaders in their respective fields. Their fundamental company level research is often non-consensus and provides guidance on overall portfolio construction and security selection.

Looking ahead, Middlefield remains committed to managing and developing new and unique investment products to assist Financial Advisors in helping clients achieve their investment objectives.

TABLE OF CONTENTS

A NOTE ON FORWARD LOOKING STATEMENTS

2022 MID-YEAR REVIEW AND OUTLOOK

Market conditions were extremely challenging for equity investors during the first half of 2022 (H1). Both the MSCI World and the S&P 500 finished the period in a bear market, down more than 20%, making it the worst start to a year since 1970. The Canadian stock market outperformed most global indices with the S&P/TSX Composite generating a total return of -9.9%.

Market volatility was driven by persistent inflation, which has reached multi-decade highs in most countries throughout the world. One of the biggest contributors has been the sudden increase in global demand. After nearly two years of pandemic-related lockdowns and restrictions, consumers started spending again. This made it challenging for providers of goods and services to ramp up capacity fast enough to meet demand and placed additional strain on global supply chains. Russia's unexpected invasion of Ukraine in late February further exacerbated inflationary forces. The attack spurred a swift response from the global community in the form of unprecedented economic sanctions in an effort to isolate Russia from the global economy. This effectively removed Russian supplies of a number of critical commodities from global markets, including oil, wheat, base metals and fertilizers. WTI crude oil and NYMEX natural gas prices both increased by approximately 46% in H1.

In response to higher-than-expected inflation, global central banks quickly pivoted to hawkish monetary policies which have led to a rapid increase in interest rates and bond yields. Both the US Federal Reserve and the Bank of Canada raised short-term borrowing rates three times in H1 by a total of 1.5% and 1.25%, respectively. US 10-year Treasury Yields rose from 1.5% at the start of the year to over 3% at the end of June while Canadian 10-Year Bond yields went from 1.4% to 3.2%. The impacts of these moves have been pervasive, including a 9.4% increase in the DXY US Dollar Index and a -14% return in Investment-Grade Credit.

Increasing interest rates have had an outsized impact on growth stocks. The Russell 1000 Value index returned -13%, significantly outperforming the Russell 1000 Growth index return of -28%. The Nasdaq Composite returned -29%, marking its worst H1 return since its inception in 1971. Defensive sectors such as utilities, consumer staples and healthcare significantly outperformed the broader market while communication services, information technology and consumer discretionary lagged. Energy, which returned 31.6%, was the only sector in the S&P 500 to post a positive return. While the market environment continues to be challenging for technology stocks, we remain highly optimistic on the long-term potential of the sector and view the current setup as attractive for patient investors. We are confident in the durability of various investment themes such as online advertising and e-commerce which are supported by structural changes in spending patterns. We are also bullish on enterprise software though we are choosing our exposures carefully. Our tech exposures are anchored by high quality industry leaders with sustainable competitive advantages.

Canadian equities performed well in H1 on a relative basis. The energy sector generated a total return of 26.3% and was the biggest positive contributor to performance. Generating unprecedented levels of cash flow, Canadian energy companies have been returning substantial amounts of excess cash to shareholders in the form of dividends and share buybacks. Utilities were the only other sector in the TSX to generate a positive return, adding 1.3%. Although the global economic outlook is uncertain, we believe Canadian equities are uniquely positioned to continue outperforming as it is a net exporter of oil and electricity.

Several of Middlefield's mutual funds benefitted from exposure to Canadian equities in H1. Canadian Dividend Growers Class (F Series) generated a total return of -2.0%, outperforming the S&P/TSX Canadian Dividend Aristocrats Index return of -7.2%. INDEXPLUS Income Fund (F Series), which is predominantly allocated to Canadian equities, generated a total return of -0.5%. Finally, Income Plus Class (F Series) returned -2.9% in H1, building upon its longstanding track record of strong risk-adjusted returns. For the month ending May 31st, Income Plus was recognized for outstanding performance and received the FundGrade A rating from Fundata.

The S&P 500 healthcare sector generated a total return of -8.3%, outperforming the S&P 500 by 11.7% and finishing as the fourth best performing sector in the index. Defensive sub-industries such as pharmaceuticals and managed care led to the upside while more cyclical industries such as medical equipment & life science tools lagged significantly. Biopharma companies sell needs-based products which benefit from inelastic demand, and are therefore more insulated from market downturns. Middlefield Healthcare Dividend Fund generated a total return of -6.4%, outperforming its benchmark, the MSCI World Healthcare Index, by 3.7%. The Fund invests in a portfolio of leading companies diversified across the global healthcare sector which are predominantly large-cap, dividend-paying issuer. Over the course of the year, and particularly during Q1, the Fund's asset allocation was shifted towards more defensive and value-oriented industries and exposure to higher growth segments such as medical equipment & services was reduced. We believe large-cap biopharma stocks are poised to outperform against the backdrop of a slowing economy but we may gradually increase exposure in H2 to some of our preferred medical equipment names that have experienced significant drawdowns.

The Middlefield Family of mutual funds, which are listed at the end of this report, currently includes nine different funds within the multi-class structure and three mutual fund trusts. The multi-class structure of Middlefield Mutual Funds enables investors to benefit from superior tax efficiencies unavailable to other forms of investment funds. In addition, almost all classes are offered in F-Series.

The Canadian real estate sector generated a total return of -21.7% in H1. US REITs performed marginally better, finishing H1 with a total return of -20.1%. We are focused on owning high-quality issuers in the current environment. In particular, REITs that are well positioned to increase rents can act as a useful hedge against inflation. We also place a high emphasis on balance sheet strength, preferring companies with lower leverage and minimal near-term debt maturities. After the recent pullback, Canadian REITs are trading at more than a 20% discount to their net asset values on average – trough valuations that compare to the depths of 2008 and 2020. While we are mindful of the macro economic challenges facing the sector today, we believe REITs are oversold and we encourage investors to opportunistically add exposure.

We continue to believe that infrastructure will remain a highly sought-after and defensive asset class. In our view, end markets with the best long-term outlooks include transportation, energy infrastructure and utilities. Companies in these areas provide highly visible, long-term cash flows and have business models that are inherently resilient against inflation. Infrastructure assets are also supported by scarcity value, with a limited number of world class assets that are viewed as attractive by not only public but also private investors across private equity and pensions. We are finding great risk / reward opportunities in the renewables space, following a period of sustained underperformance during the recent commodity bull market. With energy security top of mind, we expect that renewable additions will continue to accelerate as countries further distance themselves from Russia and aim to become more self-sufficient.

Middlefield's Global Infrastructure Fund generated a total return of -6.2% in H1. Since its inception in June 2013, the fund has generated an annualized total return of 6.7%. The Fund actively invests in high-quality, dividend-paying infrastructure companies with critical assets spanning across toll roads & airports, energy infrastructure and utilities.

We expect natural gas prices will remain elevated over the medium term. Unlike oil, Russia is unable to redirect European supply to other regions, including China, due to pipeline capacity restraints. This effectively removes a meaningful portion of global natural gas supply from the market. In addition, the European Union recently voted to keep some specific uses of natural gas and nuclear energy in its taxonomy of sustainable sources of energy. As a result, European countries will need to rely more heavily on LNG imports.

Enbridge (ENB) has long been bullish on the outlook for natural gas, starting with its acquisition of Spectra back in 2016. The outlook is more positive today now that the Russia/Ukraine conflict has placed a greater emphasis on energy security as part of the energy transition equation. ENB is well positioned to capitalize on the natural gas renaissance from expansion projects on the US Gulf Coast as well as its gas pipelines in British Columbia to support new West Coast LNG opportunities (Woodfibre LNG, Cedar LNG). This LNG buildout will benefit ENB as its footprint expands in both regions.

Outlook

We believe we are in a cyclical bear market which is a function of rising rates and inflation combined with lower profit expectations. Given the impacts that inflation and higher interest rates will have on demand, we expect a mild slowdown in economic activity this year. Much of this is already being priced in to markets today, reflected in the S&P 500 forward earnings multiple declining from 21x to below 16x. As a result, we believe downside in broad market indices should be limited from current levels and are seeing an increasingly attractive setup for equities in the latter part of the year.

Although it may not show up in near-term inflation reports given the lagging nature of data, we believe we are at peak inflation and should start to get some data points that are incrementally less hawkish throughout H2. Sell-side earnings estimates have started to come down and we do expect a deceleration in growth over the coming quarters; however, household and corporate balance sheets remain strong which backstops our view of only a mild slowdown. Against this backdrop, we are focused on companies with high margins, strong balance sheets and stable dividends.

Dean Orrico
President and CEO
Middlefield Capital Corporation

Robert F. Lauzon
Managing Director and Chief Investment Officer
Middlefield Capital Corporation

This interim management report of fund performance contains financial highlights but does not contain the annual financial statements of the investment fund. This report should be read in conjunction with the complete interim financial report of the investment fund that follows this report. The interim financial report has not been reviewed by the investment fund's external auditors.

Securityholders may contact us by calling 1-888-890-1868, by writing to us at Middlefield Group at one of the addresses on the back cover or by visiting our website at www.middlefield.com to request a copy of the investment fund's annual financial statements, proxy voting policies and procedures, proxy voting disclosure record or quarterly portfolio disclosure.

Management's Discussion of Fund Performance

Investment Objectives and Strategies
Middlefield Healthcare Dividend Fund (formerly Global Healthcare Dividend Fund) (the "Fund") is a mutual fund trust. The Fund is authorized to issue series of units designated as Series A and F. The investment objectives of the Fund are to provide holders of units with: (i) stable cash distributions; and (ii) long-term total return through distributions and capital appreciation of the Fund's investment portfolio. The Fund's investment strategy focuses on investing in dividend paying securities of global issuers that derive a significant portion of their revenue or earnings from products or services related to healthcare.

Results of Operations
Investment Performance
The net assets of the Fund decreased from $94.4 million at December 31, 2021 to $87.9 million at June 30, 2022. Net assets on a per unit basis for Series A decreased from $16.20 at December 31, 2021 to $14.85 at June 30, 2022. Net assets on a per unit basis for Series F decreased from $17.21 at December 31, 2021 to $15.87 at June 30, 2022. The Fund recorded a $6.1 million net loss on its investment portfolio during the six months ended June 30, 2022.

Revenue and Expenses
Loss before operating expenses for the six months ended June 30, 2022, amounted to $5.3 million, down from revenue of $4.1 million in 2021. The decrease was primarily due to the net loss on the Fund's investments. Operating expenses for the period ended June 30, 2022, amounted to $1.0 million up from $0.9 million in 2021. The management expense ratio ("MER") in 2022 was 2.56% for Series A and 1.46% for Series F. Distributions for the period ended June 30, 2022 amounted to $0.24 per unit for both Series A and Series F.

Trends
Healthcare's defensive attributes were on full display in H1. The S&P 500 healthcare sector outperformed the S&P 500 by 11.7% and finished as the fourth best performing sector in the index. Biopharma companies sell needs-based products which benefit from inelastic demand, and are therefore more insulated from market downturns. Biopharma companies also carry high levels of inventory and therefore have lower relative exposure to supply chain disruptions than other industries.

Related Party Transactions
Pursuant to a management agreement, Middlefield Limited (the "Manager") receives a management fee. For further details please see the "Management Fees" section of this report. Middlefield Capital Corporation ("MCC" or the "Advisor"), the advisor to the Fund and a company under common control with the Manager, receives advisory fees from the Manager out of the management fee. MCC also receives brokerage commissions from the Fund in connection with securities transactions. All brokerage commissions paid by the Fund to MCC were at or below market rates. For further details please see the notes to the financial statements.

Management Fees
Management fees are calculated at 2.0% per annum for the Series A units and 1.0% per annum for the Series F units, of the net asset value of each Series and are split between the Manager, the Advisor and investment dealers who receive trailing commissions. The Manager receives fees for the general administration of the Fund, including maintaining the accounting records, executing securities trades, monitoring compliance with regulatory requirements, and negotiating contractual agreements, among other things. The Advisor receives fees from the Manager for providing investment advice in respect of the portfolio in accordance with the investment objectives and strategies of the Fund.

Financial Highlights
Net Assets Attributable to Holders of Redeemable Units are calculated in accordance with International Financial Reporting Standards ("IFRS").

"Net Asset Value" is calculated in accordance with section 14.2 of National Instrument 81-106 "Investment Fund Continuous Disclosure" ("NI 81-106") and is used for transactional pricing purposes.

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the indicated periods. Ratios and Supplemental Data are derived from the Fund's Net Asset Value.

The Fund's Net Assets per Unit (1) – Series A

	June 30 2022(4)	December 31 2021	December 31 2020	December 31 2019	December 31 2018	December 31 2017
Net Assets Attributable to Holders of Redeemable Units, Beginning of Period	**$ 16.20**	$ 14.23	$ 13.73	$ 12.71	$ 11.74	$ 11.16
INCREASE (DECREASE) FROM OPERATIONS:						
Total Revenue	**0.12**	0.19	0.17	0.21	0.20	0.19
Total Expenses (excluding distributions)	**(0.19)**	(0.38)	(0.37)	(0.34)	(0.33)	(0.29)
Realized Gains (Losses) for the Period	**0.43**	0.70	1.43	0.33	1.05	1.14
Unrealized Gains (Losses) for the Period	**(1.45)**	1.93	(0.26)	1.25	0.44	0.08
Transaction Costs on Purchase and Sale of Investments	**-**	-	(0.02)	(0.01)	(0.01)	(0.02)
TOTAL INCREASE (DECREASE) FROM OPERATIONS (2)	**(1.11)**	2.45	0.98	1.46	1.29	0.90
DISTRIBUTIONS:						
From Net Investment Income	**-**	-	-	-	-	-
From Capital Gains	**0.24**	0.48	0.48	0.33	0.32	0.32
Return of Capital	**-**	-	-	0.11	-	-
TOTAL DISTRIBUTIONS (3)	**0.24**	0.48	0.48	0.44	0.32	0.32
Net Assets Attributable to Holders of Redeemable Units, End of Period	**$ 14.85**	$ 16.20	$ 14.23	$ 13.73	$ 12.71	$ 11.74

The Fund's Net Assets per Unit [(1)] – Series F

	June 30 2022[(4)]	December 31 2021	December 31 2020	December 31 2019	December 31 2018	December 31 2017
Net Assets Attributable to Holders of Redeemable Units, Beginning of Period	**$ 17.21**	$ 14.92	$ 14.22	$ 13.00	$ 11.87	$ 11.15
INCREASE (DECREASE) FROM OPERATIONS:						
Total Revenue	**0.13**	0.20	0.18	0.21	0.23	0.24
Total Expenses (excluding distributions)	**(0.12)**	(0.23)	(0.22)	(0.20)	(0.20)	(0.26)
Realized Gains (Losses) for the Period	**0.46**	0.75	1.48	0.35	1.01	3.68
Unrealized Gains (Losses) for the Period	**(1.62)**	2.06	(0.33)	1.31	0.37	(2.97)
Transaction Costs on Purchase and Sale of Investments	**-**	-	(0.01)	-	(0.01)	(0.02)
TOTAL INCREASE (DECREASE) FROM OPERATIONS [(2)]	**(1.10)**	2.77	1.18	1.66	1.45	1.04
DISTRIBUTIONS:						
From Net Investment Income	**0.01**	-	-	0.02	0.02	-
From Capital Gains	**0.23**	0.48	0.48	0.42	0.30	0.32
TOTAL DISTRIBUTIONS [(3)]	**0.24**	0.48	0.48	0.44	0.32	0.32
Net Assets Attributable to Holders of Redeemable Units, End of Period	**$ 15.87**	$ 17.21	$ 14.92	$ 14.22	$ 13.00	$ 11.87

(1) This information is derived from the Fund's audited annual financial statements and unaudited interim financial report.
(2) Net Assets Attributable to Holders of Redeemable Units and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of units outstanding over the financial period. This schedule is not a reconciliation of Net Asset Value since it does not reflect unitholder transactions as shown on the Statements of Changes in Net Assets Attributable to Holders of Redeemable Units and accordingly columns may not add.
(3) Distributions were paid in cash/reinvested in additional units of the Fund, or both.
(4) For the six month period ended June 30, 2022.

Ratios and Supplemental Data – Series A

	June 30 2022(4)	December 31 2021	December 31 2020	December 31 2019	December 31 2018	December 31 2017
Total Net Asset Value (000s)	**$ 55,745**	$ 61,559	$ 55,638	$ 56,998	$ 59,263	$ 64,826
Number of Units Outstanding	**3,753,928**	3,798,979	3,909,401	4,151,660	4,662,829	5,521,831
Management Expense Ratio ("MER") (1)	**2.56%**	2.56%	2.62%	2.62%	2.62%	2.54%
Trading Expense Ratio (2)	**0.05%**	0.01%	0.10%	0.04%	0.09%	0.15%
Portfolio Turnover Rate (3)	**13.67%**	13.11%	42.96%	26.72%	20.63%	48.83%
Net Asset Value per Unit	**$ 14.85**	$ 16.20	$ 14.23	$ 13.73	$ 12.71	$ 11.74

Ratios and Supplemental Data – Series F

	June 30 2022(4)	December 31 2021	December 31 2021	December 31 2019	December 31 2018	December 31 2017
Total Net Asset Value (000s)	**$ 32,171**	$ 32,814	$ 27,086	$ 24,672	$ 18,501	$ 15,917
Number of Units Outstanding	**2,026,901**	1,906,887	1,815,020	1,735,216	1,422,706	1,340,539
Management Expense Ratio ("MER") (1)	**1.46%**	1.46%	1.52%	1.50%	1.52%	1.47%
Trading Expense Ratio (2)	**0.05%**	0.01%	0.10%	0.04%	0.09%	0.15%
Portfolio Turnover Rate (3)	**13.67%**	13.11%	42.96%	26.72%	20.63%	48.83%
Net Asset Value per Unit	**$ 15.87**	$ 17.21	$ 14.92	$ 14.22	$ 13.00	$ 11.87

(1) The MER is based on total expenses (excluding distributions, commissions and other portfolio transaction costs) for the stated period and is expressed as an annualized percentage of daily average Net Asset Value during the period.

(2) The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average Net Asset Value during the period.

(3) The Fund's portfolio turnover rate indicates how actively the Fund's portfolio investments are managed. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the period. The higher the Fund's portfolio turnover rate in a period, the greater the trading costs payable by the Fund in the period, and the greater the chance of an investor receiving taxable capital gains in the period. There is not necessarily a relationship between a high turnover rate and the performance of a fund.

(4) As at June 30, 2022 or for the six month period ended June 30, 2022, as applicable.

Past Performance
The performance information shown, which is based on Net Asset Value, assumes that all distributions paid by the Fund in the periods shown were reinvested in additional securities of the Fund. The performance information does not take into account sales, redemption, distribution or other optional charges that would have reduced returns or performance. How the Fund has performed in the past does not necessarily indicate how it will perform in the future.

Year-By-Year Returns
The bar chart shows how the Fund's performance has varied from year to year for each of the years shown. The return for 2014 is not presented since it relates to a partial period. The charts indicate, in percentage terms, how much an investment made the first day of each financial period would have grown or decreased by the last day of the financial period.





* For the six month period ended June 30, 2022.

Summary of Investment Portfolio

AS AT JUNE 30, 2022

Top Twenty-Five Holdings

DESCRIPTION		% OF NET ASSET VALUE
1	UnitedHealth Group Inc.	4.9
2	AstraZeneca PLC	4.8
3	Eli Lilly & Co.	4.8
4	Merck & Co. Inc.	4.5
5	Abbvie Inc.	4.5
6	Thermo Fisher Scientific Inc.	4.4
7	Johnson & Johnson	3.9
8	Danaher Corp.	3.9
9	McKesson Corp.	3.8
10	Vertex Pharmaceuticals Inc.	3.7
11	Pfizer Inc.	3.5
12	Roche Holding AG	3.4
13	CVS Health Corp.	3.4
14	Bristol-Myers Squibb Co.	3.4
15	Sanofi	3.1
16	Edwards Lifesciences Corp.	3.1
17	Regeneron Pharmaceuticals Inc.	3.0
18	Zoetis Inc.	2.8
19	Alexandria Real Estate Equities Inc.	2.6
20	IQVIA Holdings Inc.	2.5
21	Abbott Laboratories	2.4
22	Gilead Sciences Inc.	2.3
23	DexCom Inc.	2.2
24	Medtronic PLC	2.1
25	Stryker Corp.	2.0

"Top Twenty-Five Holdings" excludes any temporary cash investments.

ASSET CLASS	% OF NET ASSET VALUE
Healthcare	94.2
Real Estate	2.6
Cash and Short-Term Investments	3.4
Other Assets (Liabilities)	(0.2)
	100.0
TOTAL NET ASSET VALUE	$ 87,916,028

The Summary of Investment Portfolio may change over time due to ongoing portfolio transactions.
Please visit www.middlefield.com for the most recent quarter-end Summary of Investment Portfolio.

INTERIM FINANCIAL REPORT

NOTICE

The accompanying unaudited financial statements of Middlefield Healthcare Dividend Fund (formerly Global Healthcare Dividend Fund) for the period ended June 30, 2022 have been prepared by management and have not been reviewed by the external auditors of the Fund.

Jeremy Brasseur
Director
Middlefield Limited

Craig Rogers
Director
Middlefield Limited

August 22, 2022

Statements of Financial Position

AS AT (In Canadian Dollars)		June 30, 2022		December 31, 2021
ASSETS				
Current Assets				
Investments at Fair Value Through Profit or Loss	**$**	**85,073,388**	$	90,850,694
Cash		**2,976,861**		3,692,083
Income and Interest Receivable		**96,244**		53,062
Prepaid Expenses		**38,971**		20,286
Subscriptions Receivable		**25,125**		2,958
Total Assets		**88,210,589**		94,619,083
LIABILITIES				
Current Liabilities				
Management Fee Payable (Note 7)		**151,788**		143,910
Accounts Payable and Accrued Liabilities		**74,292**		76,709
Redemptions Payable		**68,481**		26,343
Total Liabilities (Excluding Net Assets Attributable to Holders of Redeemable Units)		**294,561**		246,962
Net Assets Attributable to Holders of Redeemable Units	**$**	**87,916,028**	$	94,372,121
Net Assets Attributable to Holders of Redeemable Units – Series A	**$**	**55,745,277**	$	61,558,500
Net Assets Attributable to Holders of Redeemable Units – Series F	**$**	**32,170,751**	$	32,813,621
Mutual Fund Units Issued and Outstanding – Series A (Note 6)		**3,753,928**		3,798,979
Mutual Fund Units Issued and Outstanding – Series F (Note 6)		**2,026,901**		1,906,887
Net Assets Attributable to Holders of Redeemable Units per Unit – Series A	**$**	**14.85**	$	16.20
Net Assets Attributable to Holders of Redeemable Units per Unit – Series F	**$**	**15.87**	$	17.21

The accompanying notes to financial statements are an integral part of these financial statements.

Approved by the Board of Directors of Middlefield Limited, as Manager:

Director: Jeremy Brasseur

Director: Craig Rogers

INTERIM FINANCIAL REPORT

UNAUDITED

Statements of Comprehensive Income

FOR THE SIX MONTHS ENDED JUNE 30
(In Canadian Dollars)

		2022		2021
REVENUE (LOSS)				
Income from Investments	$	**832,579**	$	690,917
Interest Income for Distribution Purposes		**1,467**		979
Foreign Exchange Gain (Loss) on Cash		**(17,367)**		(470,074)
Other Changes in Fair Value of Financial Assets and Financial Liabilities at Fair Value through Profit or Loss				
Net Realized Gain (Loss) from Investment Transactions		**2,610,427**		2,100,989
Change in Net Unrealized Gain (Loss) on Investments		**(8,693,900)**		1,433,155
Change in Net Unrealized Gain (Loss) on Foreign Currency Transactions		**(901)**		334,605
Total Revenue (Loss)		**(5,267,695)**		4,090,571
OPERATING EXPENSES (Note 7)				
Advisory Fee		**17,531**		17,038
Audit Fees		**14,733**		14,966
Custodial Fees		**4,888**		4,244
Fund Administration Costs		**74,995**		68,520
Independent Review Committee Fees and Expenses		**8,092**		28,439
Legal Fees		**6,400**		6,377
Management Fee		**801,858**		736,694
Transaction Costs (Note 8)		**24,000**		8,836
Unitholder Reporting Costs		**32,675**		33,693
Total Operating Expenses		**985,172**		918,807
Profit (Loss) before Tax		**(6,252,867)**		3,171,764
Withholding Taxes		**122,260**		98,763
Profit (Loss) after Tax	$	**(6,375,127)**	$	3,073,001
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	$	**(6,375,127)**	$	3,073,001
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units – Series A	$	**(4,130,355)**	$	1,918,823
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units – Series F	$	**(2,244,772)**	$	1,154,178
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per Unit – Series A (Note 6)	$	**(1.09)**	$	0.50
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per Unit – Series F (Note 6)	$	**(1.15)**	$	0.63

The accompanying notes to financial statements are an integral part of these financial statements.

Statement of Changes in Net Assets Attributable to Holders of Redeemable Units

FOR THE SIX MONTHS ENDED JUNE 30, 2022 (In Canadian Dollars)	Series A	Series F	Total
Net Assets Attributable to Holders of Redeemable Units at Beginning of Period	**$ 61,558,500**	**$ 32,813,621**	**$ 94,372,121**
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	**(4,130,355)**	**(2,244,772)**	**(6,375,127)**
DISTRIBUTIONS TO UNITHOLDERS:			
From Net Investment Income	**-**	**(23,573)**	**(23,573)**
From Capital Gains	**(909,887)**	**(448,483)**	**(1,358,370)**
	(909,887)	**(472,056)**	**(1,381,943)**
REDEEMABLE UNIT TRANSACTIONS:			
Proceeds from Issue of Units	**2,035,188**	**3,272,625**	**5,307,813**
Reinvested Distributions	**795,848**	**333,618**	**1,129,466**
Payment on Redemption of Units	**(3,604,017)**	**(1,532,285)**	**(5,136,302)**
	(772,981)	**2,073,958**	**1,300,977**
Net Assets Attributable to Holders of Redeemable Units at End of Period	**$ 55,745,277**	**$ 32,170,751**	**$ 87,916,028**

Statement of Changes in Net Assets Attributable to Holders of Redeemable Units

FOR THE SIX MONTHS ENDED JUNE 30, 2021 (In Canadian Dollars)	Series A	Series F	Total
Net Assets Attributable to Holders of Redeemable Units at Beginning of Period	$ 55,638,036	$ 27,085,624	$ 82,723,660
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	1,918,823	1,154,178	3,073,001
DISTRIBUTIONS TO UNITHOLDERS:			
From Capital Gains	(917,748)	(443,317)	(1,361,065)
	(917,748)	(443,317)	(1,361,065)
REDEEMABLE UNIT TRANSACTIONS:			
Proceeds from Issue of Units	2,285,256	2,278,641	4,563,897
Reinvested Distributions	805,072	311,760	1,116,832
Payment on Redemption of Units	(4,236,002)	(1,958,672)	(6,194,674)
	(1,145,674)	631,729	(513,945)
Net Assets Attributable to Holders of Redeemable Units at End of Period	$ 55,493,437	$ 28,428,214	$ 83,921,651

The accompanying notes to financial statements are an integral part of these financial statements.

Statements of Cash Flows

FOR THE SIX MONTHS ENDED JUNE 30 (In Canadian Dollars)		2022		2021
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES				
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	**$**	**(6,375,127)**	$	3,073,001
Adjustments:				
Proceeds from Sale of Investments		**48,082,056**		9,805,413
Purchases of Investments		**(48,388,223)**		(9,051,730)
Foreign Exchange (Gain) Loss on Cash		**18,268**		135,469
Net Realized (Gain) Loss from Investment Transactions		**(2,610,427)**		(2,100,989)
Change in Net Unrealized (Gain) Loss on Investments		**8,693,900**		(1,433,155)
		(579,553)		428,009
Net Change in Non-Cash Working Capital		**(56,406)**		(14,280)
Net Cash from (used in) Operating Activities		**(635,959)**		413,729
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES				
Proceeds from Issue of Units		**5,285,646**		4,551,009
Payment on Redemption of Units		**(5,094,164)**		(6,102,991)
Distributions Paid		**(252,477)**		(244,233)
Net Cash from (used in) Financing Activities		**(60,995)**		(1,796,215)
Net Increase (Decrease) in Cash		**(696,954)**		(1,382,486)
Foreign Exchange Gain (Loss) on Cash		**(18,268)**		(135,469)
Cash at Beginning of Period		**3,692,083**		4,018,414
Cash at End of Period	**$**	**2,976,861**	$	2,500,459

The accompanying notes to financial statements are an integral part of these financial statements.

Schedule of Investment Portfolio

AS AT JUNE 30, 2022
(In Canadian Dollars)

Description	No. of Securities	Average Cost	Fair Value
Abbott Laboratories	15,000	$ 1,728,912	$ 2,102,306
Abbvie Inc.	20,000	2,905,039	3,951,395
Amgen Inc.	5,000	1,102,261	1,569,232
AstraZeneca PLC	25,000	2,852,683	4,229,787
Boston Scientific Corp.	30,000	1,521,139	1,442,300
Bristol-Myers Squibb Co.	30,000	2,105,089	2,979,799
CRISPR Therapeutics AG	20,000	1,398,350	1,567,813
CVS Health Corp.	25,000	2,351,177	2,988,184
Danaher Corp.	10,500	2,042,497	3,433,812
DexCom Inc.	20,000	2,203,244	1,922,809
Edwards Lifesciences Corp.	22,000	2,801,152	2,698,563
Eli Lilly & Co.	10,000	2,665,238	4,182,427
Genmab A/S	25,000	997,310	1,047,767
Gilead Sciences Inc.	25,000	2,098,014	1,993,305
GSK PLC	60,000	1,546,788	1,659,580
Humana Inc.	2,000	1,167,657	1,207,580
Intuitive Surgical Inc.	5,000	993,565	1,294,536
IQVIA Holdings Inc.	8,000	1,105,941	2,239,261
Johnson & Johnson	15,000	1,877,142	3,434,702
McKesson Corp.	8,000	1,806,442	3,366,373
Medtronic PLC	16,000	1,729,753	1,852,377
Merck & Co. Inc.	34,000	2,837,854	3,998,581
Moderna Inc.	3,000	244,942	552,811
Pfizer Inc.	45,000	2,208,706	3,043,459
Regeneron Pharmaceuticals Inc.	3,500	1,768,962	2,668,862
Roche Holding AG	7,000	2,258,740	3,004,541
Sanofi	21,000	2,314,401	2,728,369
Stryker Corp.	7,000	1,578,781	1,796,277
Thermo Fisher Scientific Inc.	5,500	1,145,090	3,854,441
UnitedHealth Group Inc.	6,500	967,985	4,306,642
Vertex Pharmaceuticals Inc.	9,000	1,514,439	3,271,471
Zoetis Inc.	11,000	1,507,094	2,439,037
HEALTHCARE: 94.1%		57,346,387	82,828,399
Alexandria Real Estate Equities Inc.	12,000	2,946,864	2,244,989
REAL ESTATE: 2.5%		2,946,864	2,244,989
TRANSACTION COSTS (NOTE 8)		(67,975)	-
TOTAL INVESTMENTS: 96.6%		60,225,276	85,073,388
CASH: 3.4%		2,976,861	2,976,861
Total Investment Portfolio, including Cash		$ 63,202,137	$ 88,050,249

1. Middlefield Healthcare Dividend Fund

Middlefield Healthcare Dividend Fund (formerly Global Healthcare Dividend Fund) (the “Fund”) is an unincorporated open-ended investment trust established by Middlefield Limited, a corporation existing under the laws of the Province of Alberta, pursuant to a supplemental declaration of trust dated December 22, 2016. From September 24, 2014 until December 20, 2016, the Fund operated as a closed-end investment trust established under the laws of the Province of Alberta. The Fund was listed on the Toronto Stock Exchange and effectively commenced operations on October 23, 2014, when it first issued units through an initial public offering. As part of the process of converting to an open-ended unit trust, the Fund was delisted from the Toronto Stock Exchange on December 19, 2016. The Fund is authorized to issue series of units designated as Series A and Series F. Each series has a different management fee rate. Middlefield Limited, a company incorporated in Alberta, is both the manager and trustee of the Fund (the “Manager”) and Middlefield Capital Corporation (“MCC”), a company under common control with the Manager, is the advisor to the Fund (the “Advisor”). The address of the Fund’s registered office is 100 King Street West, 1 First Canadian Place, Suite 5855, Toronto, Ontario. These financial statements, expressed in Canadian Dollars, were authorized for issuance by the board of directors of the Manager on August 22, 2022.

On May 31, 2022, the name of the Fund was changed to Middlefield Healthcare Dividend Fund.

2. Basis of Presentation

These financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and in accordance with International Financial Reporting Standards 34 Interim Financial Reporting (“IAS 34”) as published by the International Accounting Standards Board (“IASB”) and as required by Canadian securities legislation and the Canadian Accounting Standards Board.

3. Summary of Significant Accounting Policies

A. Basis of Accounting

IFRS 9 *Financial Instruments* (“IFRS9”)

The Fund classifies and measures financial instruments in accordance with IFRS 9, which requires assets to be carried at amortized cost or fair value, with changes in fair value recognized in profit and loss or other comprehensive income, based on the entity’s business model for managing financial assets and the contractual cash flow characteristics of the financial assets. The Fund’s financial assets and liabilities are classified at fair value through profit or loss (“FVTPL”) and amortized cost.

Classification, Measurement, Impairment and Hedge Accounting

The Fund classifies its investments in debt and equity securities based on its business model for managing those financial assets and the contractual cash flow characteristics of the financial assets. These financial assets are managed and their performance is evaluated on a fair value basis. The Fund also manages these financial assets with the objective of realizing cash flows through sales. Further, an option to irrevocably designate any equity securities at fair value through other comprehensive income (“FVOCI”) was chosen upon adoption. Consequently, these financial assets are mandatorily measured at FVTPL.

Financial assets or financial liabilities held for trading are those acquired principally for the purpose of selling or repurchasing in the near future or on initial recognition they are a part of a portfolio of identified financial instruments that the Fund manages together and has a recent actual pattern of short term profit taking. All derivatives and short positions are included in this category and mandatorily measured at FVTPL. The financial assets and liabilities measured at amortized cost include cash collateral posted on derivative positions, accrued income, due to and from brokers and other short term receivables and payables.

IFRS 9 uses the expected credit loss model (“ECL”), as the new impairment model for financial assets carried at amortized cost. The Fund’s financial assets measured at amortized cost consist of trade receivables with no financing component and which have maturities of less than 12 months, as such, it has chosen to apply the simplified ECL approach, whereby any loss allowance is recognized based on the lifetime of ECLs. Due to the high quality and short-term nature of the trade receivables, there are no expected credit losses associated with them and they are not considered impaired at the reporting dates.

The Fund does not apply general hedge accounting to any of its derivatives positions.

3. Summary of Significant Accounting Policies (continued)

B. Financial Instruments

The Fund's financial instruments may include: short-term investments, fixed income, equities, structured products including investment funds managed by the Manager, derivatives (collectively referred to as "investments"), cash, accounts receivable – portfolio securities sold, income and interest receivable, accounts receivable, subscriptions receivable, prepaid interest, prepaid expenses, loan payable, accounts payable – portfolio securities purchased, accounts payable and accrued liabilities, redemptions payable and distributions payable. The Fund recognizes financial instruments at fair value upon initial recognition, plus transaction costs in the case of financial instruments measured at amortized cost. Regular way purchases and sales of financial assets are recognized at their trade date. The Fund's investments and derivative assets and liabilities are measured at fair value. The Fund's Net Assets Attributable to Holders of Redeemable Units are measured at fair value. All other financial assets and liabilities are measured at amortized cost. Under this method, financial assets and liabilities reflect the amount required to be received or paid, discounted, when appropriate, at the contract's effective interest rate. The Fund's accounting policies for measuring the fair value of its investments and derivatives are identical to those used in measuring its net asset value ("NAV") for transactions with unitholders.

The Fund only offsets financial assets and financial liabilities if the Fund has a legally enforceable right to offset recognized amounts and either intends to settle on a net basis or to realize the asset and settle the liability simultaneously.

C. Redeemable Units and Net Assets Attributable to Holders of Redeemable Units

The Fund has two series of redeemable units in issue: Series A and Series F. Both rank pari passu in all material respects and have the same terms and conditions other than the management fee rate, which is 2.0% for Series A and 1.0% for Series F.

Redeemable units can be put back to the Fund at any time for cash equal to a proportionate share of the Fund's NAV attributable to the unit class. The redeemable units are classified as financial liabilities and are measured at the redemption amounts.

Redeemable units are issued and redeemed based on the Fund's NAV per unit, calculated by dividing the net assets of the Fund, calculated in accordance with the Fund's Simplified Prospectus, by the number of redeemable units in issue. The Fund's Simplified Prospectus requires that investment positions are valued on the basis of the last traded market price for the purpose of determining the trading NAV per unit for subscriptions and redemptions.

The financial assets and liabilities at fair value through profit or loss in the Statements of Financial Position are based on closing prices in accordance with IFRS.

Distributions are declared at the discretion of the Trustee, and are distributed by the Fund. The Trustee has changed is distribution policy of declaring distributions from quarterly to monthly beginning with a monthly distribution effective April 29, 2019. The Trustee intends to distribute any excess income and capital gains annually in December such that the Fund will not have any liability for taxes (other than those that are immediately refundable). Distribution payments may be adjusted without notice at any time as market conditions change. If the Fund does not earn enough income and capital gains to meet the distributions, it may return capital to make up the difference. Distributions to holders of redeemable units are recognized in the Statements of Changes in Net Assets Attributable to Holders of Redeemable Units.

Net assets are calculated for each series of units of the Fund. The net assets of a particular series of units are computed by calculating the value of the series' proportionate share of the assets and liabilities of the Fund common to all series. Management fees directly attributable to a series are charged to that series. Other expenses, investment income and realized and unrealized gains and losses on investments are allocated proportionately to each series based upon the relative net assets of each series.

3. Summary of Significant Accounting Policies (continued)

D. Fair Value Measurement

The Fund's own credit risk and the credit risk of the counterparty are taken into account in determining the fair value of financial assets and financial liabilities, including derivative instruments. Investments and futures contracts are valued at fair value using the policies described below.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets is based on quoted market prices at the close of trading on the reporting date. The Fund uses the last traded market price for both financial assets and financial liabilities where the last traded price falls within that day's bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, the Manager determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances.

Futures contracts are marked to market each valuation day according to the gain or loss that would have been realized if the contracts had been closed out. Gains or losses arising from futures contracts are recorded as unrealized gain (loss) on futures contracts and shown as an asset (liability) on the Statements of Financial Position until the contracts are closed out or expire, at which time the gains (losses) are realized.

The fair value of financial assets and liabilities that are not traded in an active market (for example, over-the-counter derivatives) is determined by using valuation techniques. The Fund uses a variety of methods and makes assumptions that are based on market conditions existing at each reporting date. Valuation techniques used include the use of comparable recent arm's length transactions, reference to other instruments that are substantially the same, discounted cash flow analysis, option pricing models and other valuation techniques commonly used by market participants making the maximum use of market inputs and relying as little as possible on entity specific inputs.

E. Investment Transactions and Income Recognition

Investment transactions are accounted for as of the trade date and any realized gains or losses from such transactions are calculated on an average cost basis. Average cost does not include amortization of premiums or discounts on fixed income securities with the exception of zero coupon bonds. The change in the difference between fair value and average cost of the investments is recorded as an unrealized gain (loss) on investments. Income from investments is recognized on the ex-dividend or ex-distribution date. Interest income for distribution purposes shown on the Statements of Comprehensive Income represents the interest received on bank deposits by the Fund and, if the Fund holds fixed income investments, coupon interest accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed income securities except for zero coupon bonds which are amortized on a straight line basis. The interest income for distribution purposes is the tax basis of calculating the interest received and which is subject to tax. Income distributions received are treated consistently with dividends and interest and recorded in income in the Statements of Comprehensive Income.

F. Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per Unit

Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per unit in the Statements of Comprehensive Income represents the increase (decrease) in Net Assets Attributable to Holders of Redeemable Units for each series divided by the average units outstanding for each series during the period.

G. Income Taxes

The Fund qualifies as a mutual fund trust under the provisions of the Income Tax Act (Canada) and accordingly, is subject to tax on its income, including net realized capital gains in the taxation period, which is not paid or payable to its unitholders as at the end of the taxation period. It is the intention of the Fund to distribute all of its net income and sufficient net realized capital gains so that the Fund will not be subject to income taxes other than foreign withholding taxes, if applicable. Accordingly, no provision for income taxes is required.

The Fund currently incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income and gains are recorded on a gross basis and the related withholding taxes are shown separately in the Statements of Comprehensive Income.

Distributions received from investments in trust units that are treated as a return of capital for tax purposes are used to reduce the average cost of the underlying investments on the Schedule of Investment Portfolio.

3. Summary of Significant Accounting Policies (continued)

H. Foreign Currency Translation

Foreign currency amounts are translated into Canadian dollars as follows: fair value of investments, forward currency contracts and other assets and liabilities, at the closing rate of exchange on each business day; income and expenses, and purchases, sales and settlements of investments, at the rate of exchange prevailing on the respective dates of such transactions.

I. Critical Accounting Estimates and Judgments

The preparation of financial statements requires management to use judgment in applying its accounting policies and to make estimates and assumptions about the future. The following discusses the most significant accounting judgments and estimates that the Fund has made in preparing the financial statements:

Determination of Functional Currency

'Functional currency' is the currency of the primary economic environment in which the Fund operates. If indicators of the primary economic environment are mixed, then management uses its judgment to determine the functional currency that most faithfully represents the economic effect of the underlying transactions, events, and conditions. The majority of the Fund's investments and transactions are denominated in Canadian dollars. Investor subscriptions and redemptions are also received and paid in Canadian dollars. Accordingly, management has determined that the functional currency of the Fund is Canadian dollars.

Fair Value Measurement of Derivatives and Securities Not Quoted in an Active Market

The Fund may hold financial instruments that are not quoted in active markets, including derivatives. Fair values of such instruments are determined using valuation techniques and may be determined using reputable pricing sources (such as pricing agencies) or indicative prices from market makers. Broker quotes as obtained from the pricing sources may be indicative and not executable or binding. Where no market data is available, the Fund may value positions using its own models, which are usually based on valuation methods and techniques generally recognized as standard within the industry. The models used to determine fair values are validated and periodically reviewed by experienced personnel of the Manager, independent of the party that created them. The models used for private equity securities are based mainly on earnings multiples adjusted for a lack of marketability as appropriate.

Models use observable data, to the extent practicable. However, areas such as credit risk (both own and counterparty), volatilities and correlations require the Manager to make estimates. Changes in assumptions about these factors could affect the reported fair values of financial instruments. The Fund considers observable data to be market data that is readily available, regularly distributed and updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. Refer to Note 4 for further information about the fair value measurement of the Fund's financial instruments.

J. Securities Lending

The Fund may enter into securities lending transactions. These transactions involve the temporary exchange of securities as collateral with a commitment to deliver the same securities on a future date. Income is earned from these transactions in the form of fees paid by the counterparty and, in certain circumstances, interest paid on securities held as collateral. Income earned from these transactions is recognized on an accrual basis and is included in the Statements of Comprehensive Income.

4. Fair Value Disclosure
The Fund classifies fair value measurements within a hierarchy which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The fair values of the Fund's financial instruments are classified into levels using the following fair value hierarchy:

Level 1	Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.
Level 2	Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.
Level 3	Inputs that are unobservable and where there is little, if any, market activity. Inputs into the determination of fair value require significant management judgement or estimation.

The Fund's investments at fair value as at June 30, 2022 and December 31, 2021 trade in active markets and are therefore classified as Level 1.

All fair value measurements are recurring. The carrying values of cash, income and interest receivable, prepaid expenses, subscriptions receivable, management fee payable, accounts payable and accrued liabilities, redemptions payable, and the Fund's obligation for Net Assets Attributable to Holders of Redeemable Units approximate their fair values due to their short-term nature.

Fair values are classified as Level 1 when the related security is actively traded and a quoted price is available. If an instrument classified as Level 1 subsequently ceases to be actively traded, it is transferred out of Level 1. In such cases, instruments are reclassified into Level 2, unless the measurement of its fair value requires the use of significant unobservable inputs, in which case it is classified as Level 3.

The Fund's policy is to recognize transfers in and out of the fair value hierarchy levels as at the end of the reporting period for transfers between Levels 1 and 2 and as at the date of the transfer for transfers in and out of Level 3. No transfers between levels have occurred during the period ended June 30, 2022 and the year ended December 31, 2021.

5. Financial Risk Management
In the normal course of business the Fund is exposed to a variety of financial risks: price risk, liquidity risk, foreign exchange rate risk, credit risk and concentration risk. The Fund's primary risk management objective is to protect earnings and cash flow and, ultimately, unitholder value. Risk management strategies, as discussed below, are designed and implemented to ensure the Fund's risks and related exposures are consistent with its objectives and risk tolerance.

Most of the Fund's risks are derived from its investments. The value of the investments within the Fund's portfolio can fluctuate on a daily basis as a result of changes in interest rates, economic conditions, commodity prices, the market and company news related to specific securities held by the Fund. The investments are made in accordance with the Fund's risk management policies. The policies establish investment objectives, strategies, criteria and restrictions. The objectives of these policies are to identify and mitigate investment risk through a disciplined investment process and the appropriate structuring of each transaction.

A. Price Risk
Price risk is the risk that changes in the prices of the Fund's investments will affect the Fund's income or the value of its financial instruments. The Fund's price risk is driven primarily by volatility in commodity and equity prices. Rising commodity and equity prices may increase the price of an investment while declining commodity and equity prices may have the opposite effect. The Fund mitigates price risk by making investing decisions based upon various factors, including comprehensive fundamental analysis prepared by industry experts to forecast future commodity and equity price movements. The Fund's market positions are monitored on a daily basis by the portfolio manager and regular financial reviews of publicly available information related to the Fund's investments are performed to ensure that any risks are within established levels of risk tolerance. The Fund is exposed to price risk through the following financial instrument:

	June 30, 2022	December 31, 2021
Investments at FVTPL	$ 85,073,388	$ 90,850,694

Based on the above exposure at June 30, 2022, a 10% increase or decrease in the prices of the Fund's investments would result in a $8,507,339 (December 31, 2021 - $9,085,069) increase or decrease in total equity of the Fund, with all other factors held constant.

5. Financial Risk Management (continued)

B. Liquidity Risk

Liquidity risk is defined as the risk that the Fund may not be able to settle or meet its obligations when due. The Fund is exposed to daily cash redemptions of its units. The units of the Fund are issued and redeemed on demand at the NAV per unit. All other obligations of the Fund are due within one period. Liquidity risk is managed by investing the majority of the Fund's assets in investments that are traded in an active market and can be readily sold. The Fund retains sufficient cash to maintain liquidity and comply with liquidity requirements as outlined by securities legislation and its investment policies.

The Fund may invest in securities that are not traded on a public stock exchange or that may be illiquid. As a result, the Fund may not be able to dispose of these investments in a timely manner. The Fund mitigates this risk through active management, which involves detailed analysis of such private entities to ensure they are financially sound and would be attractive to potential investors if a sale is necessary. The Fund's investment policies and securities legislation limit the amount invested in illiquid securities and these limits are monitored. The Fund did not hold any illiquid securities as at June 30, 2022 and December 31, 2021.

The tables below present the Fund's financial liabilities based on the remaining period to the contractual maturity date. The amounts in the tables reflect the contractual undiscounted cash flows.

As at June 30, 2022

Financial Liabilities	Less than 1 Month	1 to 3 Months	3 Months to 1 Year	Total
Management Fee Payable	$ 151,788	$ -	$ -	$ 151,788
Accounts Payable and Accrued Liabilities	74,292	-	-	74,292
Redemptions Payable	68,481	-	-	68,481
Net Assets Attributable to Holders of Redeemable Units	87,916,028	-	-	87,916,028
Total	$ 88,210,589	$ -	$ -	$ 88,210,589

As at December 31, 2021

Financial Liabilities	Less than 1 Month	1 to 3 Months	3 Months to 1 Year	Total
Management Fee Payable	$ 143,910	$ -	$ -	$ 143,910
Accounts Payable and Accrued Liabilities	76,709	-	-	76,709
Redemptions Payable	26,343	-	-	26,343
Net Assets Attributable to Holders of Redeemable Units	94,372,121	-	-	94,372,121
Total	$ 94,619,083	$ -	$ -	$ 94,619,083

5. Financial Risk Management (continued)

C. Foreign Exchange Rate Risk

Foreign exchange rate risk describes the impact on the underlying value of financial instruments due to foreign exchange rate movements. The Canadian dollar is the Fund's functional and reporting currency. Foreign investments, commodities, cash, receivables and payables denominated in foreign currencies are affected by changes in the value of the Canadian dollar compared to foreign currencies. As a result, financial assets may depreciate/appreciate in the short-term due to the strengthening/weakening of the Canadian dollar against other currencies, and the reverse would be true for financial liabilities. The Fund's exposure to foreign exchange rate risk relates primarily to its investment in securities, which are denominated in various foreign currencies. The Fund has not hedged its exposure to currency fluctuations; however, it closely monitors relevant foreign exchange currency movements. The Fund is exposed to foreign exchange rate risk through the following financial instruments denominated in various foreign currencies:

As at June 30, 2022

Currency	Investments at FVTPL	Cash	Income and Interest Receivable	Total Exposure
U.S. Dollar	$ 73,451,110	$ 814,378	$ 83,084	$ 74,348,572
U.K. Pound Sterling	5,889,368	-	13,159	5,902,527
European Euro	2,728,369	-	-	2,728,369
Swiss Franc	3,004,541	-	-	3,004,541
Total	$ 85,073,388	$ 814,378	$ 96,243	$ 85,984,009

As at December 31, 2021

Currency	Investments at FVTPL	Cash	Income and Interest Receivable	Total Exposure
U.S. Dollar	$ 81,005,223	$ 10,165	$ 33,558	$ 81,048,946
U.K. Pound Sterling	3,876,236	-	19,504	3,895,740
European Euro	2,290,336	-	-	2,290,336
Swiss Franc	3,678,899	-	-	3,678,899
Total	$ 90,850,694	$ 10,165	$ 53,062	$ 90,913,921

Based on the above exposure at June 30, 2022, a 10% increase or decrease in the Canadian dollar against the respective foreign currencies would result in a $8,598,401 (December 31, 2021 – $9,091,392) decrease or increase in total equity of the Fund, with all other factors held constant.

D. Credit Risk

Credit risk represents the financial loss that the Fund would experience if a counterparty to a financial instrument failed to meet its obligations to the Fund. The Fund is exposed to credit risk on its debt instruments, derivative assets, cash and cash equivalents and other short term trade receivables. The Fund measures credit risk and lifetime ECLs related to the trade receivables using historical analysis and forward looking information in determining the ECL. The carrying amounts of financial assets represent the maximum credit exposure. All transactions executed by the Fund in listed securities are settled upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase only once the broker has received the securities. The trade will fail if either party fails to meet its obligations. There is no significant credit risk related to the Fund's receivables.

The Fund has established various internal controls to help mitigate credit risk, including prior approval of all investments by the Advisor whose mandate includes conducting financial and other assessments of these investments on a regular basis. The Fund has also implemented policies which ensure that investments can only be made with counterparties that have a minimum acceptable credit rating.

E. Concentration Risk

The Fund is exposed to the possible risk inherent in the concentration of the investment portfolio in a small number of industries or investment sectors. The Manager moderates this risk through careful selection of securities in several investment sectors. At June 30, 2022 and December 31, 2021, the percentages of the Fund's total equity invested in each investment sector were as follows:

Sector	As a % of Net Assets June 30, 2022	December 31, 2021
Healthcare	94.2	93.2
Real Estate	2.6	3.1
Total	96.8	96.3

6. Unitholders' Equity

The capital of the Fund is divided into Series A and Series F with each series having an unlimited number of securities. Changes in issued mutual fund units of the Fund are summarized as follows:

	Number of Units – Series A	
	June 30, 2022	December 31, 2021
Units Outstanding at Beginning of Period	3,798,979	3,909,401
Units Issued	132,629	280,578
Reinvested Distributions	52,638	108,883
Total	185,267	389,461
Units Redeemed	(230,318)	(499,883)
Net Increase (Decrease)	(45,051)	(110,422)
Units Outstanding at End of Period	3,753,928	3,798,979

	Number of Units – Series F	
	June 30, 2022	December 31, 2021
Units Outstanding at Beginning of Period	1,906,887	1,815,020
Units Issued	194,460	254,371
Reinvested Distributions	20,708	40,639
Total	215,169	295,010
Units Redeemed	(95,154)	(203,143)
Net Increase (Decrease)	120,015	91,867
Units Outstanding at End of Period	2,026,901	1,906,887

The average number of Series A and Series F units outstanding during the period ended June 30, 2022 were 3,796,224 and 1,959,801 (June 30, 2021 – 3,838,441 and 1,845,825), respectively. These numbers were used to calculate the respective Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per unit.

7. Management Fee and Operating Expenses

The Manager provides investment and administrative services to the Fund. In consideration for such services the Manager receives a monthly fee in arrears based on each series of units as a percentage of the average daily NAV of the series. The management fee for Series A is 2.0% per annum and for Series F is 1.0% per annum. Common expenses incurred by the Fund are allocated among the series on a pro-rata basis among all units of all series. The Manager is reimbursed for reasonable costs related to maintaining the Fund and preparation and distribution of financial statements and other documents to unitholders. For the period ended June 30, 2022, management fees before the absorption of expenses amounted to $0.8 million. The Fund is responsible for the payment of all expenses relating to the operation of the Fund and the carrying on of its business.

8. Transaction Costs

Brokerage commissions and other transaction costs paid in connection with securities transactions during the period ended June 30, 2022 amounted to $24,000 (June 30, 2021 – $8,836). Included in this amount is $4,454 (June 30, 2021 – $2,925) in brokerage commissions that were paid to MCC. All brokerage commissions paid by the Fund to MCC were at or below market rates. Brokerage commissions and other transaction costs are expensed and recorded in the Statements of Comprehensive Income.

9. Securities Lending

The Fund has entered into a securities lending program with its custodian, RBC Investor Services Trust, in order to earn additional revenue. The aggregate market value of all securities loaned by the Fund will not exceed 50% of the fair value of the assets of the Fund. The Fund will receive collateral of at least 105% of the fair value of the securities on loan. Collateral held is generally comprised of cash and securities of, or guaranteed by, the Government of Canada or a province thereof, or the United States government or its agencies. Securities lending income reported in the Statements of Comprehensive Income is net of a securities lending charge which the Fund's custodian, RBC Investor Services Trust, is entitled to receive.

There were no securities lending charges during the periods ended June 30, 2022 and June 30, 2021.

There were no securities loaned and collateral held as at June 30, 2022 and December 31, 2021.

10. Capital Management

The Fund's capital is its Net Assets Attributable to Holders of Redeemable Units representing unitholders' equity. The Fund's objective when managing capital is to safeguard the Fund's ability to continue as a going concern in order to provide returns for unitholders, maximize unitholder value and maintain financial strength.

The Fund is not subject to any externally imposed capital requirements. The Fund's overall strategy with respect to capital risk management remains unchanged from the year ended December 31, 2021.

11. Loss Carryforwards

At December 31, 2021, the Fund had no non-capital losses (December 31, 2020- $nil) and no capital losses (December 31, 2020 - $nil) available for carryforward tax purposes.

12. Distributions to Unitholders

The Fund pays distributions to unitholders in accordance with its investment objectives. Distributions of the Fund, unless otherwise specified by the unitholder, are automatically reinvested in additional units of the Fund at the NAV without sales charge. Distributions per Series A unit and Series F unit of $0.04 were paid to unitholders of the Fund at the end of each month during the period ended June 30, 2022 (June 30, 2021 – $0.04).

Distributions to Unitholders – Series A	2022	2021
From Capital Gains		
Total	$ 909,887	$ 917,748
Per Unit	0.24	0.24

Distributions to Unitholders – Series F	2022	2021
From Net Investment Income		
Total	$ 23,573	$ -
Per Unit	0.01	-
From Capital Gains		
Total	448,483	443,317
Per Unit	0.23	0.24

13. The outbreak of the novel coronavirus (COVID-19) has led to governments around the world enacting emergency measures that resulted in business disruptions, volatility in markets and a global economic slowdown. The Manager uses judgment in assessing the impact from such events on assumptions and estimates applied in reporting the assets and liabilities in the Fund's financial statements at June 30, 2022. The duration and full extent of impact of the COVID-19 pandemic are unknown at the reporting date and it is therefore not possible to reliably estimate the entire impact on the financial results and position of the Fund in future period

MIDDLEFIELD FUNDS FAMILY |

EXCHANGE - TRADED FUNDS (ETFs)	TSX Stock Symbol
• Middlefield Healthcare Dividend ETF (formerly Healthcare & Life Sciences ETF)	MHCD
• Middlefield Health & Wellness ETF	HWF
• Middlefield Innovation Dividend ETF (formerly Global Innovation Dividend Fund)	MINN
• Middlefield Sustainable Global Dividend ETF (formerly Global Dividend Growers Income Fund)	MDIV
• Middlefield Sustainable Infrastructure Dividend ETF (formerly Sustainable Infrastructure Dividend Fund)	MINF
• Middlefield Real Estate Dividend ETF (formerly Middlefield REIT INDEXPLUS ETF)	MREL
• Middlefield U.S. Equity Dividend ETF (formerly Middlefield American Core Dividend ETF)	MUSA

TSX-LISTED FUNDS	
• E Split Corp.	ENS | ENS.PR.A
• International Clean Power Dividend Fund	CLP.UN
• Middlefield Global Real Asset Fund	RA.UN
• MINT Income Fund	MID.UN
• Real Estate Split Corp. (formerly Real Estate & E-Commerce Split Corp.)	RS | RS.PR.A
• Sustainable Agriculture & Wellness Dividend Fund	AGR.UN
• Sustainable Innovation & Health Dividend Fund	SIH.UN
• Sustainable Real Estate Dividend Fund	MSRE.UN
• Workplace Technology Dividend Fund	WORK.UN

MIDDLEFIELD MUTUAL FUNDS TRUST FUNDS Series A Units	Fund Code FE/LL/DSC
• Middlefield Healthcare Dividend Fund (formerly Global Healthcare Dividend Fund)	MID 325/327/330
• INDEXPLUS Income Fund	MID 435/437/440
• Middlefield Global Infrastructure Fund	MID 510/519/520

Series F Units	
• Middlefield Healthcare Dividend Fund (formerly Global Healthcare Dividend Fund)	MID 326
• INDEXPLUS Income Fund	MID 436
• Middlefield Global Infrastructure Fund	MID 501

MIDDLEFIELD MUTUAL FUNDS CORPORATE CLASS FUNDS Series A Shares	Fund Code FE/LL/DSC
• Middlefield Canadian Dividend Growers Class	MID 148/449/450
• Middlefield Global Agriculture Class	MID 161/163/166
• Middlefield Global Dividend Growers Class	MID 181/183/186
• Middlefield Global Energy Transition Class (commenced May 31, 2022)	MID 265
• Middlefield Real Estate Dividend Class (formerly Middlefield Global Real Estate Class)	MID 600/649/650
• Middlefield High Interest Income Class	MID 400/424/425
• Middlefield Income Plus Class	MID 800/849/850
• Middlefield Innovation Dividend Class (commenced May 31, 2022)	MID 925
• Middlefield U.S. Equity Dividend Class (formerly Middlefield U.S. Dividend Growers Class)	MID 710/719/720

Series F Shares	
• Middlefield Canadian Dividend Growers Class	MID 149
• Middlefield Global Agriculture Class	MID 162
• Middlefield Global Dividend Growers Class	MID 182
• Middlefield Global Energy Transition Class (commenced May 31, 2022)	MID 266
• Middlefield Real Estate Dividend Class (formerly Middlefield Global Real Estate Class)	MID 601
• Middlefield Income Plus Class	MID 801
• Middlefield Innovation Dividend Class (commenced May 31, 2022)	MID 926
• Middlefield U.S. Equity Dividend Class (formerly Middlefield U.S. Dividend Growers Class)	MID 701

RESOURCE FUNDS

- Discovery 2021 Short Duration LP
- MRF 2021 Resource Limited Partnership
- MRF 2022 Resource Limited Partnership

INTERNATIONAL FUNDS	
• Middlefield Canadian Income PCC	London UK Stock Exchange (LSE) Symbol:MCT

www.middlefield.com
invest@middlefield.com
(888) 890-1868

MIDDLEFIELD

TORONTO, CANADA
Middlefield Limited / Middlefield Capital Corporation
First Canadian Place
58th Floor, P.O. Box 192
Toronto, Ontario
Canada M5X 1A6
Telephone (416) 362-0714
Fax (416) 362-7925

LONDON, ENGLAND
Middlefield International Limited
288 Bishopsgate
London, England
EC2M 4QP
Telephone (0207) 814-6644
Fax (0207) 814-6611

SAN FRANCISCO, USA
Middlefield Financial Services Inc.
50 California Street, Suite 1500,
San Francisco, California
USA 94111
Telephone (415) 835-1308
Fax (415) 835-1350